Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTENASDAQ:IMTXNASDAQ:KYMRNASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$69.48+1.3%$58.07$31.01▼$86.53$2.21B-1.5450,497 shs51,827 shsIMTXImmatics$4.55+2.2%$5.40$4.06▼$13.77$543.07M0.83587,414 shs198,780 shsKYMRKymera Therapeutics$35.10+5.5%$37.82$29.07▼$53.27$2.28B2.22593,115 shs647,091 shsMIRMMirum Pharmaceuticals$45.03+2.2%$47.31$23.14▼$54.23$2.21B1.04525,810 shs789,310 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+2.48%+14.73%+19.26%+6.95%+53.83%IMTXImmatics-1.11%+2.53%-17.59%-40.82%-63.67%KYMRKymera Therapeutics+0.76%+8.44%-10.85%-26.09%-21.33%MIRMMirum Pharmaceuticals+2.44%-2.57%-13.71%+1.03%+63.55%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLTEBelite Bio2.2477 of 5 stars3.53.00.00.02.10.80.6IMTXImmatics2.066 of 5 stars3.62.00.00.02.61.70.0KYMRKymera Therapeutics1.458 of 5 stars3.40.00.00.02.81.70.0MIRMMirum Pharmaceuticals4.1253 of 5 stars3.50.00.04.23.63.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 3.00Buy$96.3338.65% UpsideIMTXImmatics 3.20Buy$16.67266.30% UpsideKYMRKymera Therapeutics 2.86Moderate Buy$56.6961.52% UpsideMIRMMirum Pharmaceuticals 3.09Buy$58.2029.25% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, KYMR, BLTE, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/28/2025KYMRKymera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $60.002/28/2025MIRMMirum PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$66.00 ➝ $72.002/27/2025MIRMMirum PharmaceuticalsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $55.001/21/2025BLTEBelite BioBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$57.00 ➝ $79.001/21/2025KYMRKymera TherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.00 ➝ $60.0012/27/2024KYMRKymera TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$60.00 ➝ $60.00(Data available from 3/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/AIMTXImmatics$115.50M4.70N/AN/A$2.88 per share1.58KYMRKymera Therapeutics$47.07M48.43N/AN/A$7.12 per share4.93MIRMMirum Pharmaceuticals$336.89M6.55N/AN/A$5.33 per share8.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$31.63M-$1.11N/AN/AN/AN/A-31.94%-30.73%3/17/2025 (Estimated)IMTXImmatics-$104.98M-$0.66N/AN/AN/A-47.94%-15.90%-9.38%3/20/2025 (Estimated)KYMRKymera Therapeutics-$146.96M-$2.97N/AN/AN/A-191.26%-24.96%-20.27%5/1/2025 (Estimated)MIRMMirum Pharmaceuticals-$163.41M-$1.85N/AN/AN/A-31.69%-41.22%-14.81%5/14/2025 (Estimated)Latest IMTX, KYMR, BLTE, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2025N/AIMTXImmatics-$0.03N/AN/AN/A$16.16 millionN/A3/17/2025N/ABLTEBelite Bio-$0.30N/AN/AN/AN/AN/A2/27/2025Q4 2024KYMRKymera Therapeutics-$0.76-$0.88-$0.12-$0.88$14.81 million$7.39 million2/26/2025Q4 2024MIRMMirum Pharmaceuticals-$0.27-$0.49-$0.22-$0.49$96.64 million$99.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A30.7330.73IMTXImmaticsN/A3.983.98KYMRKymera TherapeuticsN/A8.558.55MIRMMirum Pharmaceuticals1.333.343.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%IMTXImmatics64.41%KYMRKymera TherapeuticsN/AMIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%IMTXImmatics3.30%KYMRKymera Therapeutics15.82%MIRMMirum Pharmaceuticals22.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableIMTXImmatics260119.36 million115.42 millionOptionableKYMRKymera Therapeutics17064.94 million54.52 millionOptionableMIRMMirum Pharmaceuticals14049.01 million37.03 millionOptionableIMTX, KYMR, BLTE, and MIRM HeadlinesRecent News About These CompaniesMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 10 at 8:00 PM | businesswire.comAigen Investment Management LP Takes Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)March 9 at 4:59 AM | marketbeat.comInsider Buying: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Director Purchases 1,335 Shares of StockMarch 7, 2025 | marketbeat.comPatrick J. Heron Buys 1,335 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) StockMarch 7, 2025 | insidertrades.comCandriam S.C.A. Sells 78,744 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)March 7, 2025 | marketbeat.comFY2025 EPS Estimates for MIRM Boosted by Cantor FitzgeraldMarch 3, 2025 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Certara (CERT), Lantheus (LNTH) and Mirum Pharmaceuticals (MIRM)March 3, 2025 | markets.businessinsider.comEquities Analysts Issue Forecasts for MIRM FY2025 EarningsMarch 3, 2025 | marketbeat.comEquities Analysts Offer Predictions for MIRM Q3 EarningsMarch 3, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $57.60 Consensus Price Target from BrokeragesMarch 3, 2025 | americanbankingnews.comAnalyst Estimates: Here's What Brokers Think Of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) After Its Full-Year ReportMarch 1, 2025 | finance.yahoo.comMirum Pharmaceuticals (NASDAQ:MIRM) Price Target Raised to $72.00 at HC WainwrightMarch 1, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Trading Down 8.2% After Earnings MissFebruary 28, 2025 | marketbeat.comMirum Pharmaceuticals price target raised to $65 from $63 at Morgan StanleyFebruary 28, 2025 | markets.businessinsider.comRobert W. Baird Issues Positive Forecast for Mirum Pharmaceuticals (NASDAQ:MIRM) Stock PriceFebruary 28, 2025 | marketbeat.comEvercore ISI Reaffirms Their Buy Rating on Mirum Pharmaceuticals (MIRM)February 28, 2025 | markets.businessinsider.comMirum Pharmaceuticals price target raised to $55 from $50 at BairdFebruary 28, 2025 | markets.businessinsider.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Average Rating of "Buy" by BrokeragesFebruary 28, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Releases Quarterly Earnings Results, Misses Estimates By $0.22 EPSFebruary 27, 2025 | marketbeat.comMIRM's Q4 Loss Wider Than Expected, Revenues Beat EstimatesFebruary 27, 2025 | zacks.comPhocas Financial Corp. Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)February 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMTX, KYMR, BLTE, and MIRM Company DescriptionsBelite Bio NASDAQ:BLTE$69.48 +0.87 (+1.27%) Closing price 04:00 PM EasternExtended Trading$69.79 +0.31 (+0.45%) As of 07:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Immatics NASDAQ:IMTX$4.55 +0.10 (+2.25%) Closing price 04:00 PM EasternExtended Trading$4.58 +0.03 (+0.64%) As of 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Kymera Therapeutics NASDAQ:KYMR$35.10 +1.83 (+5.50%) Closing price 04:00 PM EasternExtended Trading$35.04 -0.06 (-0.17%) As of 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$45.03 +0.97 (+2.20%) Closing price 04:00 PM EasternExtended Trading$45.03 0.00 (0.00%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ramaco Resources Pins Hopes on Coal's Untapped Potential Beyond a Market Correction, Moves to Make Now NVIDIA Stock Remains Stunningly Undervalued—Here’s Why Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy 3 Stocks Institutions Are Quietly Dumping Marvell’s 40% Drop Presents a Compelling Buying Opportunity These 3 Dividend Stocks Jumped 15% in a Month—More to Come? Why Wayfair Stock May Be a Hidden Gem for Value Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
